StartsidaHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Föregående stängning
25,85 €
Dygnsintervall
25,67 € - 25,67 €
Årsintervall
19,52 € - 36,69 €
Börsvärde
3,58 md USD
P/E-tal
-
Direktavkastning
-
Primär börs
NASDAQ
Aktuellt
Ekonomi
Resultaträkning
Intäkter
Nettoinkomst
(USD) | mars 2024info | Förändring Y/Y |
---|---|---|
Intäkter | — | — |
Rörliga kostnader | 126,19 mn | 28,63 % |
Nettoinkomst | −125,30 mn | −357,42 % |
Nettovinstmarginal | — | — |
Vinst per aktie | −1,02 | −326,67 % |
EBITDA | −121,67 mn | −339,34 % |
Giltig skattesats | — | — |
Balansräkning
Totala tillgångar
Totala ansvarsskyldigheter
(USD) | mars 2024info | Förändring Y/Y |
---|---|---|
Kontanta och kortsiktiga investeringar | 520,91 mn | 8,30 % |
Totala tillgångar | 955,15 mn | 7,16 % |
Totala ansvarsskyldigheter | 459,74 mn | 7,87 % |
Totala tillgångar | 495,40 mn | — |
Utestående aktier | 124,20 mn | — |
P/B | 6,63 | — |
Avkastning på tillgångar | −39,90 % | — |
Avkastning på kapital | −43,18 % | — |
Kassaflöde
Förändring i nettokassa
(USD) | mars 2024info | Förändring Y/Y |
---|---|---|
Nettoinkomst | −125,30 mn | −357,42 % |
Kontanter från verksamhet | −92,38 mn | −191,68 % |
Kontanter från investering | −268,94 mn | −645,70 % |
Kontanter från finansiering | 430,78 mn | 82 741,73 % |
Förändring i nettokassa | 69,49 mn | 203,27 % |
Fritt kassaflöde | −91,82 mn | −262,49 % |
Om
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Grundades
1 jan. 2004
Huvudkontor
Hemsida
Anställda
525